




# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/633,438	08/01/2003	Robert H. Oakley	033072-044	4547

7590 10/03/2005

Dorsey & Whitney LLP  
Intellectual Property Department  
555 California Street  
Suite 1000  
San Francisco, CA 94101

EXAMINER

ULM, JOHN D

ART UNIT PAPER NUMBER

1649

DATE MAILED: 10/03/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION	ATTORNEY DOCKET NO.
---------------------------------	-------------	---	---------------------

EXAMINER
----------

ART UNIT	PAPER
----------	-------

20050929

DATE MAILED:

**Please find below and/or attached an Office communication concerning this application or proceeding.**

**Commissioner for Patents**

The reply filed on 29 August of 2005 is not fully responsive to the prior Office Action because "Class B GPCR" is clearly not a disclosed species of receptor protein "as listed in Figures 3 to 6" of the instant specification, "a eukaryotic cell" is clearly not a disclosed species of cell "as listed in paragraphs 00112 and 00113", "an optical marker" is clearly not a species of marker "as listed in paragraph 00116", and "arrestin" is not a species of protein as listed in paragraph 00115. "Human A1 adenosine receptor" would be an example of a disclosed species of receptor, "an HEK cell" would be an example of a disclosed species of cell, "beta-galactosidase" would be an example of a disclosed species of marker, and "β arrestin 1" would be an example of a disclosed species of protein associated with a desensitization pathway. Since the period for reply set forth in the prior Office action has expired, this application will become abandoned unless applicant corrects the deficiency and obtains an extension of time under 37 CFR 1.136(a).

The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. In no case may an applicant reply outside the SIX (6) MONTH statutory period or obtain an extension for more than FIVE (5) MONTHS beyond the date for reply set forth in an Office action. A fully responsive reply must be timely filed to avoid abandonment of this application.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to John D. Ulm whose telephone number is (571) 272-0880. The examiner can normally be reached on 9:00AM to 5:30PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres can be reached on (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

JOHN ULM  
PRIMARY EXAMINER  
GROUP 1600